

# CONTENTS

|                                                       | Page No.    |
|-------------------------------------------------------|-------------|
| Acknowledgements                                      | i-ii        |
| Contents                                              | iii-vii     |
| List of Tables                                        | viii-xi     |
| List of Figures                                       | xii-xxii    |
| Abbreviations                                         | xxiii-xxvii |
| <br>                                                  |             |
| CHAPTER 1 REVIEW OF LITERATURE                        | 1-53        |
| 1.1 Cardiovascular diseases                           | 1           |
| 1.2 Economic impact                                   | 3           |
| 1.3 Myocardial Infarction                             | 3           |
| 1.3.1 Pathophysiology of Myocardial Infarction        | 4           |
| 1.3.2 Mechanisms of myocardial injury                 | 5           |
| 1.3.3 Risk factors and Symptoms of MI                 | 7           |
| 1.3.4 Diagnosis and Laboratory finding of MI          | 8           |
| 1.3.5 Treatment of myocardial infarction              | 9           |
| 1.4 Reactive oxygen species and oxidative stress      | 11          |
| 1.4.1 Sources of Reactive Oxygen Species              | 12          |
| 1.4.3 Molecular damage induced by free radicals       | 14          |
| 1.5 Reactive oxygen species and cardiovascular system | 16          |
| 1.5.1 ROS and calcium ions                            | 19          |
| 1.5.2 ROS and lipotoxicity                            | 19          |
| 1.5.3 Nitric oxide and cardiac function               | 20          |
| 1.5.4 C-Reactive protein                              | 21          |
| 1.5.5 Myeloperoxidase                                 | 22          |
| 1.5.6 Apoptosis                                       | 23          |

|                                 |                                                                     |        |
|---------------------------------|---------------------------------------------------------------------|--------|
| 1.6                             | Catecholamine induced myocardial necrosis                           | 25     |
| 1.6.1                           | Mechanism of ISO induced myocardial infarction                      | 27     |
| 1.7                             | Defenses against oxidative stress                                   | 30     |
| 1.8                             | Natural antioxidants a promising ray                                | 33     |
| 1.8.1                           | Antioxidants in ISO induced Myocardial infarction                   | 34     |
| 1.9                             | Vitamin E ( $\alpha$ -tocopherol)                                   | 37     |
| 1.10                            | Green tea ( <i>Camellia sinensis</i> )                              | 39     |
| 1.11                            | Lycopene #                                                          | 42     |
| 1.12                            | <i>Lagenaria siceraria</i> (Bottle Gourd)                           | 46     |
| 1.13                            | Pomegranate ( <i>Punica Granatum</i> ) #                            | 50     |
| CHAPTER 2 INTRODUCTION          |                                                                     | 54-62  |
| CHAPTER 3 AIMS AND OBJECTIVES   |                                                                     | 63-64  |
| CHAPTER 4 MATERIALS AND METHODS |                                                                     | 65-101 |
| 4.1.1                           | Drugs                                                               | 65     |
| 4.1.2                           | Chemicals                                                           | 65     |
| 4.1.3                           | Sources of diagnostic kits                                          | 66     |
| 4.1.4                           | Collection and authentication of <i>Lagenaria siceraria</i> Fruits  | 66     |
| 4.1.4.2                         | Test dose preparation                                               | 67     |
| 4.1.5                           | Experimental animals                                                | 67     |
| 4.1.6                           | Fixation of optimum dosage of drugs                                 | 68     |
| 4.1.7                           | Experimental design                                                 | 68     |
| 4.2                             | Assessment of Biochemical parameters                                | 71     |
| 4.2.1                           | Removal and Processing of Serum and Tissues for Various Estimations | 71     |
| 4.2.3                           | Assessment of biochemical parameters                                | 72     |
| 4.2.4                           | Hemodynamic measurements                                            | 72     |

|         |                                                                     |       |
|---------|---------------------------------------------------------------------|-------|
| 4.2.4.1 | Electrocardiographic measurements                                   | 72    |
| 4.2.4.2 | Measurement of Blood pressure                                       | 72    |
| 4.2.5   | Assessment of serum cardiac marker enzymes                          | 72-73 |
| 4.2.5.1 | Assay of Aspartate transaminase (AST/GOT)                           | 72    |
| 4.2.5.2 | Assay of Alanine transaminase (ALT/GPT)                             | 72    |
| 4.2.5.3 | Assay of Alkaline phosphatase (ALP)                                 | 73    |
| 4.2.5.4 | Assay of Lactate dehydrogenase (LDH)                                | 73    |
| 4.2.5.5 | Assay of CreatinekinaseMB (CKMB)                                    | 73    |
| 4.2.5.6 | Assay of serum total protein (TP)                                   | 73    |
| 4.2.6.6 | Assay of Uric acid (UA)                                             | 73    |
| 4.2.6   | Assessment of lipid peroxidation and endogenous antioxidants        | 73-79 |
| 4.2.6.1 | Assay of Lipid Peroxidation (LPO)                                   | 73    |
| 4.2.6.2 | Assay of Reduced Glutathione (GSH)                                  | 74    |
| 4.2.6.3 | Assay of Glutathione peroxidase (GPx)                               | 75    |
| 4.2.6.4 | Assay of Glutathione Stransferase (GST)                             | 76    |
| 4.2.6.5 | Assay of Superoxide dismutase (SOD)                                 | 77    |
| 4.2.6.6 | Assay of Catalase (CAT)                                             | 78    |
| 4.2.6.7 | Estimation of Vitamin E                                             | 79    |
| 4.2.7   | Assessment of membrane bound phosphatases                           | 79-83 |
| 4.2.7.1 | Assay of Na <sup>+</sup> K <sup>+</sup> ATPas                       | 79    |
| 4.2.7.2 | Assay of Ca <sup>2+</sup> ATPase                                    | 80    |
| 4.2.7.3 | Assay of Mg <sup>2+</sup> ATPase                                    | 81    |
| 4.2.7.4 | Determination of Inorganic Phosphorus                               | 82    |
| 4.2.7.5 | Estimation of Na <sup>+</sup> , K <sup>+</sup> and Ca <sup>++</sup> | 83    |
| 4.2.7.6 | Estimation of tissue Protein                                        | 83    |
| 4.2.8   | Separation of Lactate dehydrogenase (LDH) isoenzymes                | 84    |
| 4.2.9   | Lipid Profile                                                       | 85-87 |

|          |                                                                   |        |
|----------|-------------------------------------------------------------------|--------|
| 4.2.9.1  | Extraction of Lipids from heart tissue                            | 85     |
| 4.2.9.2  | Estimation of Total cholesterol (TC)                              | 86     |
| 4.2.9.3  | Estimation of Triglyceride (TG)                                   | 86     |
| 4.2.9.4  | Estimation of High density lipoproteins (HDL)                     | 86     |
| 4.2.9.5  | Estimation of LDL and VLDL                                        | 86     |
| 4.2.9.6  | Estimation of Phospholipids (PL)                                  | 86     |
| 4.2.9.7  | Estimation of Free Fatty acids (FFA)                              | 87     |
| 4.2.10   | Lipid metabolizing enzymes                                        | 88-90  |
| 4.2.10.1 | Estimation of tissue Lecithin cholesterol acyl transferase (LCAT) | 88     |
| 4.2.10.2 | Estimation of Tissue Cholesterol ester synthase (CES)             | 89     |
| 4.2.10.3 | Estimation of Tissue Lipoprotein Lipase (LPL)                     | 90     |
| 4.2.11   | Measurement of Myeloperoxidase (MPO) activity                     | 91     |
| 4.2.12   | Measurement of tissue nitrite level                               | 92     |
| 4.2.13   | Measurement of Creactive protein (CRP)                            | 92     |
| 4.2.14   | Histopathology study                                              | 93-95  |
| 4.2.14.1 | Haemotoxyline and eosin staining                                  | 93     |
| 4.2.14.2 | Masson's trichrome staining                                       | 94     |
| 4.2.14.3 | Periodic acid Schiff's staining                                   | 95     |
| 4.2.15   | DNA fragmentation Analysis by Gel Electrophoresis                 | 96     |
| 4.2.16   | Macroscopic enzyme mapping (TTC Staining)                         | 97     |
| 4.2.17   | Estimation of Caspase-3 protease level                            | 97     |
| 4.3      | In vitro antioxidant study                                        | 98-102 |
| 4.3.1    | DPPH radical scavenging assay                                     | 98     |
| 4.3.2    | Superoxide radical scavenging assay                               | 99     |
| 4.3.3    | Nitric oxide scavenging assay                                     | 100    |
| 4.3.4    | Lipid peroxidation in rat liver homogenate                        | 101    |
| 4.4      | Statistical Analysis                                              | 102    |

|           |                                      |         |
|-----------|--------------------------------------|---------|
| CHAPTER 5 | RESULTS                              | 103-223 |
| 5.1       | Pilot study for dose fixation        | 103-106 |
| 5.2       | Effect of Vit.E and GT               | 107-135 |
| 5.3       | Effect of Vit.E and LYP              | 136-163 |
| 5.4       | Effect of Vit.E and PGFE             | 164-191 |
| 5.5       | Effect of Vit.E and LSFJ             | 192-219 |
| 5.6       | <i>In vitro</i> antioxidant activity | 220-223 |
| CHAPTER 6 | DISCUSSION                           | 224-252 |
| CHAPTER 7 | SUMMARY AND CONCLUSION               | 253-262 |
|           | BIBLIOGRAPHY                         | 263-315 |
|           | PUBLICATIONS AND PRESENTATIONS       | 316-317 |